ROSEMARY FORDJOUR: Open Payments
NPI 1205141165 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,479 in 105 payments from 15 companies in 2025. Trend: 2023 $2,088 · 2024 $2,629 · 2025 $2,479
Food & beverage: $2,479
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $429 |
| Otsuka America Pharmaceutical, Inc. | 12 | $373 |
| Axsome Therapeutics, Inc. | 14 | $271 |
| Collegium Pharmaceutical, Inc. | 13 | $265 |
| ABBVIE INC. | 16 | $223 |
| Neurocrine BioSciences, Inc. | 8 | $208 |
| E.R. Squibb & Sons, L.L.C. | 3 | $153 |
| Alkermes, Inc. | 4 | $102 |
| Bausch Health US, LLC | 4 | $89 |
| Vanda Pharmaceuticals Inc. | 4 | $88 |
Products named: CAPLYTA, REXULTI, Auvelity, Jornay PM, VRAYLAR, INGREZZA, COBENFY, FANAPT.
Industry payments across NY — which companies pay providers there.
